The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Multiple Sclerosis, Relapsing-Remitting

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Multiple Sclerosis, Relapsing-Remitting


Psychiatry related information on Multiple Sclerosis, Relapsing-Remitting


High impact information on Multiple Sclerosis, Relapsing-Remitting


Chemical compound and disease context of Multiple Sclerosis, Relapsing-Remitting


Biological context of Multiple Sclerosis, Relapsing-Remitting


Anatomical context of Multiple Sclerosis, Relapsing-Remitting


Gene context of Multiple Sclerosis, Relapsing-Remitting


Analytical, diagnostic and therapeutic context of Multiple Sclerosis, Relapsing-Remitting


  1. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. Fridkis-Hareli, M., Santambrogio, L., Stern, J.N., Fugger, L., Brosnan, C., Strominger, J.L. J. Clin. Invest. (2002) [Pubmed]
  2. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Rudick, R.A., Ransohoff, R.M., Peppler, R., VanderBrug Medendorp, S., Lehmann, P., Alam, J. Ann. Neurol. (1996) [Pubmed]
  3. Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Durán, I., Martínez-Cáceres, E.M., Río, J., Barberà, N., Marzo, M.E., Montalban, X. Brain (1999) [Pubmed]
  4. Multiple sclerosis: magnetization transfer histogram analysis of segmented normal-appearing white matter. Catalaa, I., Grossman, R.I., Kolson, D.L., Udupa, J.K., Nyul, L.G., Wei, L., Zhang, X., Polansky, M., Mannon, L.J., McGowan, J.C. Radiology. (2000) [Pubmed]
  5. Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation. Racke, M.K., Martin, R., McFarland, H., Fritz, R.B. J. Neuroimmunol. (1992) [Pubmed]
  6. MRI and cognitive patterns in relapsing-remitting multiple sclerosis. Pugnetti, L., Mendozzi, L., Motta, A., Cattaneo, A., Biserni, P., Caputo, D., Cazzullo, C.L., Valsecchi, F. J. Neurol. Sci. (1993) [Pubmed]
  7. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Durelli, L., Verdun, E., Barbero, P., Bergui, M., Versino, E., Ghezzi, A., Montanari, E., Zaffaroni, M. Lancet (2002) [Pubmed]
  8. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Panitch, H.S., Hirsch, R.L., Haley, A.S., Johnson, K.P. Lancet (1987) [Pubmed]
  9. Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Mertin, J., Rudge, P., Kremer, M., Healey, M.J., Knight, S.C., Compston, A., Batchelor, J.R., Thompson, E.J., Halliday, A.M., Denman, M., Medawar, P.B. Lancet (1982) [Pubmed]
  10. Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Stern, J.N., Illés, Z., Reddy, J., Keskin, D.B., Sheu, E., Fridkis-Hareli, M., Nishimura, H., Brosnan, C.F., Santambrogio, L., Kuchroo, V.K., Strominger, J.L. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  11. Treatment of multiple sclerosis with the pregnancy hormone estriol. Sicotte, N.L., Liva, S.M., Klutch, R., Pfeiffer, P., Bouvier, S., Odesa, S., Wu, T.C., Voskuhl, R.R. Ann. Neurol. (2002) [Pubmed]
  12. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Harris, J.O., Frank, J.A., Patronas, N., McFarlin, D.E., McFarland, H.F. Ann. Neurol. (1991) [Pubmed]
  13. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Weber, F., Polak, T., Günther, A., Kubuschok, B., Janovskaja, J., Bitsch, A., Poser, S., Rieckmann, P. Ann. Neurol. (1998) [Pubmed]
  14. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Rieckmann, P., Albrecht, M., Kitze, B., Weber, T., Tumani, H., Broocks, A., Lüer, W., Helwig, A., Poser, S. Ann. Neurol. (1995) [Pubmed]
  15. Inhibition of autoimmune encephalomyelitis by a tetracycline. Popovic, N., Schubart, A., Goetz, B.D., Zhang, S.C., Linington, C., Duncan, I.D. Ann. Neurol. (2002) [Pubmed]
  16. Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Martínez-Cáceres, E.M., Río, J., Barrau, M., Durán, I., Borrás, C., Tintoré, M., Montalban, X. Ann. Neurol. (1998) [Pubmed]
  17. Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. De Stefano, N., Bartolozzi, M.L., Nacmias, B., Zipoli, V., Mortilla, M., Guidi, L., Siracusa, G., Sorbi, S., Federico, A., Amato, M.P. Arch. Neurol. (2004) [Pubmed]
  18. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Wergeland, S., Beiske, A., Nyland, H., Hovdal, H., Jensen, D., Larsen, J.P., Marøy, T.H., Smievoll, A.I., Vedeler, C.A., Myhr, K.M. Eur. J. Neurol. (2005) [Pubmed]
  19. Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis. Mahovic, D., Petravic, D., Petelin, Z., Zurak, N., Horvat, G., Hajnsek, S. Clinical neurology and neurosurgery. (2004) [Pubmed]
  20. Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Prat, A., Al-Asmi, A., Duquette, P., Antel, J.P. Ann. Neurol. (1999) [Pubmed]
  21. Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice. Stevens, D.B., Chen, K., Seitz, R.S., Sercarz, E.E., Bronstein, J.M. J. Immunol. (1999) [Pubmed]
  22. Cross-reactive TCR responses to self antigens presented by different MHC class II molecules. Mycko, M.P., Waldner, H., Anderson, D.E., Bourcier, K.D., Wucherpfennig, K.W., Kuchroo, V.K., Hafler, D.A. J. Immunol. (2004) [Pubmed]
  23. Decreases in T-cell tumor necrosis factor alpha binding with interferon beta treatment in patients with multiple sclerosis. Bongioanni, P., Mosti, S., Moscato, G., Lombardo, F., Manildo, C., Meucci, G. Arch. Neurol. (1999) [Pubmed]
  24. Chemokine receptors associated with immunity within and outside the central nervous system in early relapsing-remitting multiple sclerosis. Wang, H.Y., Matsui, M., Araya, S., Onai, N., Matsushima, K., Saida, T. J. Neuroimmunol. (2002) [Pubmed]
  25. Genomic effects of IFN-beta in multiple sclerosis patients. Weinstock-Guttman, B., Badgett, D., Patrick, K., Hartrich, L., Santos, R., Hall, D., Baier, M., Feichter, J., Ramanathan, M. J. Immunol. (2003) [Pubmed]
  26. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Leppert, D., Ford, J., Stabler, G., Grygar, C., Lienert, C., Huber, S., Miller, K.M., Hauser, S.L., Kappos, L. Brain (1998) [Pubmed]
  27. Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis. Holz, A., Bielekova, B., Martin, R., Oldstone, M.B. J. Immunol. (2000) [Pubmed]
  28. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. Rieckmann, P., Weber, F., Günther, A., Martin, S., Bitsch, A., Broocks, A., Kitze, B., Weber, T., Börner, T., Poser, S. J. Neuroimmunol. (1996) [Pubmed]
  29. Interferon beta1a treatment modulates TH1 expression in gammadelta + T cells from relapsing-remitting multiple sclerosis patients. Elliott, C.L., El-Touny, S.Y., Filipi, M.L., Healey, K.M., Leuschen, M.P. J. Clin. Immunol. (2001) [Pubmed]
  30. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S., Nahler, G., Mamoli, B. Lancet (1997) [Pubmed]
  31. Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1. Johnson, K.P. Ann. Neurol. (1994) [Pubmed]
  32. Failure of copolymer I to inhibit the human T-cell response to myelin basic protein. Burns, J., Littlefield, K. Neurology (1991) [Pubmed]
  33. Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS. Audoin, B., Ibarrola, D., Ranjeva, J.P., Confort-Gouny, S., Malikova, I., Ali-Chérif, A., Pelletier, J., Cozzone, P. Human brain mapping. (2003) [Pubmed]
  34. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. Yu, M., Nishiyama, A., Trapp, B.D., Tuohy, V.K. J. Neuroimmunol. (1996) [Pubmed]
WikiGenes - Universities